Medicenna Therapeutics (MDNA) News Today → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free MDNA Stock Alerts C$2.82 +0.38 (+15.57%) (As of 03:59 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMedicenna Therapeutics (TSE:MDNA) Hits New 52-Week High at $2.62americanbankingnews.com - April 28 at 5:00 AMCanadian Investment Regulatory Organization Trading Halt - MDNAca.finance.yahoo.com - April 26 at 8:19 AMMedicenna Therapeutics Announces CA$20 Million Investment from RA Capital Managementfinance.yahoo.com - April 26 at 8:19 AMMedicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)finance.yahoo.com - April 9 at 7:03 PMMedicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)finance.yahoo.com - April 9 at 2:02 PMMedicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)theglobeandmail.com - March 27 at 2:25 PMMedicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meetingfinance.yahoo.com - March 6 at 4:05 PMMedicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumorsfinance.yahoo.com - February 13 at 7:44 AMMedicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumabfinanznachrichten.de - January 9 at 9:21 AMMedicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumabfinance.yahoo.com - January 9 at 9:21 AMAll You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to Buyfinance.yahoo.com - November 20 at 1:29 PMMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlightsfinanznachrichten.de - November 14 at 3:13 PMMedicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meetingfinance.yahoo.com - November 9 at 9:49 AMMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)tmcnet.com - October 24 at 8:18 AMMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)finance.yahoo.com - October 24 at 8:18 AMMedicenna Therapeutics Corp.: Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officerfinanznachrichten.de - October 10 at 9:52 AMMedicenna Therapeutics (MDNA) Price Target Increased by 34.63% to 3.93nasdaq.com - October 5 at 7:03 AMMedicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapyfinance.yahoo.com - October 3 at 7:30 AMMedicenna Therapeutics Corp.: Medicenna Announces Results of Annual and Special Meeting of Shareholdersfinanznachrichten.de - September 29 at 11:32 PMMedicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapyfinance.yahoo.com - September 28 at 8:17 AMIs Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?finance.yahoo.com - September 26 at 12:43 PMMedicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 9:13 AMMedicenna Therapeutics gets new CFOmsn.com - August 28 at 9:08 AMMedicenna Announces the Appointment of Jeff Caravella as Chief Financial Officerfinance.yahoo.com - August 28 at 9:08 AMClosing Bell: Medicenna Therapeutics Corp up on Wednesday (MDNA)theglobeandmail.com - August 24 at 1:27 AMBloom Burton Thinks Medicenna Therapeutics Corp’s Stock is Going to Recovermarkets.businessinsider.com - August 13 at 8:29 AMMedicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Studyfinance.yahoo.com - August 9 at 9:27 AMMedicenna Therapeutics (MDNA) Price Target Increased by 5.55% to 3.54msn.com - August 2 at 5:14 AMHC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price Targetbenzinga.com - June 28 at 8:49 AMH.C. Wainwright Maintains Their Buy Rating on Medicenna Therapeutics Corp (MDNA)markets.businessinsider.com - June 28 at 8:49 AMClosing Bell: Medicenna Therapeutics Corp up on Tuesday (MDNA)theglobeandmail.com - April 19 at 9:25 AMClosing Bell: Medicenna Therapeutics Corp up on Monday (MDNA)theglobeandmail.com - April 18 at 1:28 AMClosing Bell: Medicenna Therapeutics Corp down on Thursday (MDNA)theglobeandmail.com - April 8 at 12:31 AMMedicenna Therapeutics Corp. (NASDAQ:MDNA) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - February 8 at 2:44 PMMedicenna Therapeutics Earnings Previewbenzinga.com - February 6 at 1:39 PMEarnings Preview For Medicenna Therapeuticsbenzinga.com - February 6 at 1:39 PMMedicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023finance.yahoo.com - January 26 at 8:50 AMMedicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meetingfinance.yahoo.com - November 10 at 5:04 PMMedicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - November 8 at 2:31 PMEarnings Outlook For Medicenna Therapeuticsmsn.com - November 3 at 6:48 PMMedicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirementfinance.yahoo.com - October 28 at 7:49 AMMDNA: Confirmed Partial Response in Pancreatic Cancer Patient…finance.yahoo.com - October 6 at 11:18 AMMedicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meetingfinance.yahoo.com - October 5 at 9:00 AMMedicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Studyfinance.yahoo.com - September 28 at 12:47 PMMedicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trialfinance.yahoo.com - September 13 at 7:50 AMMedicenna to Present at Investor and Scientific Conferences in Septemberfinance.yahoo.com - September 8 at 10:05 AMMDNA: Awaiting Scan Results for Unconfirmed Partial Response in ABILITY Trial…finance.yahoo.com - August 23 at 4:15 PMMedicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlightsfinance.yahoo.com - August 15 at 7:22 AMMedicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipelinefinance.yahoo.com - August 11 at 3:45 PMMedicenna Announces the Launch of a Marketed Underwritten Public Offering of Unitsfinance.yahoo.com - August 8 at 6:10 PM Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Email Address $21,000 in profits in six weeks? (Ad)On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges. Click here for details. MDNA Media Mentions By Week MDNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDNA News Sentiment▼0.000.40▲Average Medical News Sentiment MDNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDNA Articles This Week▼00▲MDNA Articles Average Week Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sernova News Oncolytics Biotech News Theratechnologies News ProMIS Neurosciences News Small Pharma News Microbix Biosystems News Fennec Pharmaceuticals News HLS Therapeutics News Cardiol Therapeutics News Zentek News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:MDNA) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersAI “wealth window” is closing June 25thParadigm PressThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
